Did you hear? Genmab’s website has a new stories page showcasing our Extra[Not]Ordinary™ people. Our website highlights how our unstoppable teams are dedicated to expanding our pipeline of antibody medicines and leveraging innovative technologies to make a difference for patients with cancer and other serious diseases. Click the link below to read our stories on the newest innovations and latest insights on how Genmab is working to transform lives. http://gmab.ly/aIUf50Sj80W #innovation #CommunityatGenmab
Om os
We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer
- Websted
-
http://www.genmab.com
Eksternt link til Genmab
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 1.001 – 5.000 medarbejdere
- Hovedkvarter
- Copenhagen V
- Type
- Aktieselskab
Beliggenheder
Medarbejdere hos Genmab
-
Hinrich Göhlmann
Scientific Director specializing in 𝐇𝐢𝐠𝐡-𝐃𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 | Bridging Science, Data, and Technology
-
Amy D.
Director, Digital Products, Experience Management @ Genmab | Digital Transformation
-
Javier Pintado
Vice President, Global Marketing at Genmab
-
Caroline Eilering
Opdateringer
-
Welcome to Genmab’s Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines. #culture #news #healthcare
-
Hear from Robyn Bilmes, Senior Vice President, Head of Medical Affairs, who discusses our latest research in #bloodcancer. As #ASCO24 wraps up, learn more about our #oncology pipeline: http://gmab.ly/IaOs50S9Ao2
-
We are thrilled to celebrate our 25-year milestone by ringing the Nasdaq Copenhagen bell today. Over our 25-year history, we have had a laser sharp focus on harnessing the power of human antibodies to develop innovative antibody therapeutics. Today our innovations power eight approved antibody-based medicines for the treatment of cancer and other serious diseases. Learn more about us: www.genmab.com
-
-
Celebrating 25 years of innovation, determination, integrity and one team spirit! As we completed our 25-year milestone this year, we want to honor and recognize the team members who have been with us since the very beginning of our remarkable journey. Thank you, for your dedication, hard work and passion that make us extra[not]ordinary™. Egon van Boxtel, Arnout Gerritsen, Michelle Pleiter, Eefje Melgert, Ruby De Ridder, Jolanda Gerritsen, Sandra Hellwig, Barbara Brouwer, Rikke Ren, and Vibeke Leth. Learn more about our unstoppable team: www.genmab.com #Genmab25 #CommunityatGenmab
-
We’re committed to our goal of deploying our expertise in "knock-your-socks-off” (KYSO®) antibodies to turn science into medicine. We are looking forward to sharing the latest data from our #hematology research at European Hematology Association (EHA) Congress. #EHA24 #Oncology #Biotech Visit us at GO3 Exhibition Hall 9 and learn more here: https://bit.ly/43lvdBO.
-
-
Genmab is proud to join National Coalition for Cancer Survivorship this National Cancer Survivors Day in celebrating the strength, resilience, and courage of cancer survivors everywhere. #NCSD2024 #CancerSurvivorsDay #CancerSurvivorshipMonth
June 2 is National Cancer Survivors Day! Let’s join together to celebrate survivorship and those who’ve supported us along the way. Share a moment from your survivorship experience or a message of support for cancer survivors using #CancerSurvivorsDay2024 and tag friends to spread positivity and encouragement throughout the day. #NCSD2024 #CancerSurvivorship
-
-
At Genmab, we’re committed to collaborating with patient advocacy groups and professional societies to learn from their perspectives with the goal of supporting patients and care partners. Thank you to all the leaders for taking the time to meet and inspire us at ASCO this year! #ASCO2024
-
-
We are delighted to announce the launch of our new global corporate website which showcases our commitment to improve the lives of patients through innovative and differentiated antibody therapeutics. Click the link below to explore our engaging new content and learn more about us: www.genmab.com #innovation #CommunityatGenmab
-
At Genmab, patients are at the center of everything we do and we believe it is important for us to share their stories and perspective, as we hope it can inspire patients on similar journeys. In honor of #NationalCancerSurvivor Day in the U.S., we sat down with Genmab Clinical Trial Manager, Keshia Carpenter, to learn about the pivotal moment in her journey where she transitioned from a cancer survivor to a “thriver.” Watch below to hear what thriving means to her. #InspiredByPatients #PatientsFirst
Tilsvarende sider
Finansiering
Genmab
5 runder i alt
Læs mere på crunchbase
Seneste runde
Post IPO-egenkapital
Eksternt Crunchbase-link til seneste finansieringsrunde
134.000.000,00 US$